重组人干扰素α1b联合TP方案治疗卵巢癌的疗效观察
|
摘要
目的探讨重组人干扰素α1b注射液联合紫杉醇注射液和卡铂注射液(方案)TP治疗卵巢癌的临床疗效。方法选取2016年1月—2017年1月咸宁市第一人民医院收治的卵巢癌患者120例为研究对象,采用随机数字法将所有患者分为对照组和治疗组,每组各60例。对照组静脉滴注紫杉醇注射液,135~175 mg/m~2加入到生理盐水500 mL中,间隔1 h静脉滴注卡铂注射液,75 mg/m~2。治疗组在对照组治疗的基础上皮下注射重组干扰素α1b注射液,30~50μg/次,1次/2 d。两组患者均治疗16周后评价疗效。观察两组的临床疗效,比较两组的健康状况调查简表(SF-36)评分。结果治疗后,对照组和治疗组的临床有效率(ORR)分别为30.00%、56.67%,疾病控制率(CBR)分别为66.67%、88.33%,两组比较差异有统计学意义(P<0.05)。治疗后,两组躯体功能评分、认知功能评分、社会功能评分、角色功能评分、情绪功能评分均明显升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组SF-36评分指标明显高于对照组,两组比较差异具有统计学意义(P<0.05)。结论重组人干扰素α1b注射液联合TP方案治疗卵巢癌具有较好的临床疗效,可改善患者生活质量,安全性较好,具有一定临床推广应用价值。
Objective To investigate the effect of Recombinant Human Interferon α1 b Injection combined with Paclitaxel Injection and Carboplatin Injection(TP scheme) in treatment of ovarian cancer. Methods Patients(120 cases) with ovarian cancer in the First People's Hospital of Xianning from January 2016 to January 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Paclitaxel Injection, 135 — 175 mg/m~2 added into normal saline 500 mL, and after 1 h, patients in the control group were iv administered with Carboplatin Injection, 75 mg/m~2. Patients in the treatment group were sc administered with Recombinant Human Interferon α1 b Injection on the basis of the control group, 30 — 50 μg/time, twice daily. Patients in two groups were treated for 16 weeks. After treatment, the clinical efficacies were evaluated, and the SF-36 scores in two groups were compared. Results After treatment, the ORR in the control and treatment groups were 30.00% and 56.67%, respectively, and the CBR in the control and treatment groups were 66.67% and 88.33%, respectively, and there was difference between two groups(P < 0.05). After treatment, somatic function scores, cognitive function scores, social function scores, role function scores, and emotional function scores in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And SF-36 scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Recombinant Human Interferon α1 b Injection combined with TP scheme has clinical curative effect in treatment of ovarian cancer, can improve the quality of life of patients, with good safety, which has a certain clinical application value.
Objective To investigate the effect of Recombinant Human Interferon α1 b Injection combined with Paclitaxel Injection and Carboplatin Injection(TP scheme) in treatment of ovarian cancer. Methods Patients(120 cases) with ovarian cancer in the First People's Hospital of Xianning from January 2016 to January 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Paclitaxel Injection, 135 — 175 mg/m~2 added into normal saline 500 mL, and after 1 h, patients in the control group were iv administered with Carboplatin Injection, 75 mg/m~2. Patients in the treatment group were sc administered with Recombinant Human Interferon α1 b Injection on the basis of the control group, 30 — 50 μg/time, twice daily. Patients in two groups were treated for 16 weeks. After treatment, the clinical efficacies were evaluated, and the SF-36 scores in two groups were compared. Results After treatment, the ORR in the control and treatment groups were 30.00% and 56.67%, respectively, and the CBR in the control and treatment groups were 66.67% and 88.33%, respectively, and there was difference between two groups(P < 0.05). After treatment, somatic function scores, cognitive function scores, social function scores, role function scores, and emotional function scores in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And SF-36 scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Recombinant Human Interferon α1 b Injection combined with TP scheme has clinical curative effect in treatment of ovarian cancer, can improve the quality of life of patients, with good safety, which has a certain clinical application value.
引文
[1]邹爽爽,张广美.大网膜切除在早期上皮性卵巢癌中的临床价值研究进展[J].中国临床研究,2017,30(6):847-850.
[2]李芳菲,郭飞,田文艳,等.难治性卵巢癌的内分泌治疗[J].中国妇产科临床杂志,2018,19(1):89-91.
[3]贺凌云,朱炜,罗君玲.单周与3周紫杉醇联合卡铂方案治疗卵巢癌临床疗效分析[J].中国现代医药杂志,2015,17(9):12-15.
[4]陈为,王善林,周龙书,等.紫杉醇联合卡铂周疗和三周疗法治疗上皮性卵巢癌的疗效比较[J].中国现代医生,2013,51(17):37-39.
[5]王丹丹,史长松.重组人干扰素α-1b雾化治疗小儿呼吸道病毒感染性疾病临床对照研究[J].中国基层医药,2014,30(31):5387-5389.
[6]夏六兵,龙洲,张腾,等.干扰素α-1b联合环氧化酶-2抑制剂对肾癌细胞及其裸鼠移植瘤的抑制作用[J].局解手术学杂志,2016,25(3):157-162.
[7]杨学宁,吴一龙.实体瘤治疗疗效评价标准—RECIST[J].循证医学,2004,4(2):85-90.
[8]万崇华,方积干,汤学良,等.SF-36量表用于肝癌患者生活质量测定的效果评价[J].肿瘤,2005,25(5):492-494.
[9]图妮沙古丽·阿卜拉江.卵巢癌早期诊断相关因子研究进展[J].新乡医学院学报,2013,30(10):835-837.
[10]付清茹,齐红岩,荣安娜.晚期卵巢上皮癌新辅助化疗的研究进展[J].医学综述,2017,23(5):891-895.
[11]靳亚阁,唐其柱.干扰素基因刺激蛋白的研究进展[J].医学综述,2017,23(20):3973-3978.
[12]杨文艺,胡镜宙.干扰素和自噬在肿瘤免疫微环境中的研究进展[J].医学研究生学报,2017,30(3):319-323.
[13]方煜蓉.重组人干扰素α-1b注射液联合聚甲酚磺醛溶液治疗宫颈HPV感染临床观察[J].中国现代医药杂志,2012,14(12):76-77.
[14]郭若一,韩嫣,胡洁,等.胞质DNA受体及其对干扰素调控作用研究进展[J].国际免疫学杂志,2014,37(6):479-484.
[15]Kiyota T,Takahashi Y,Watcharanurak K,et al.Enhancement of anticancer effect of interferon-γgene transfer against interferon-γ-resistant tumor by depletion of tumor-associated macrophages[J].Mol Pharm,2014,11(5):1542-1549.
[16]张雪,顾觉奋.埃博霉素类药物在治疗非小细胞肺癌方面研究进展:抗紫杉醇耐药有效的新颖微管蛋白抑制剂[J].国外医药:抗生素分册,2013,34(1):47-48.
[2]李芳菲,郭飞,田文艳,等.难治性卵巢癌的内分泌治疗[J].中国妇产科临床杂志,2018,19(1):89-91.
[3]贺凌云,朱炜,罗君玲.单周与3周紫杉醇联合卡铂方案治疗卵巢癌临床疗效分析[J].中国现代医药杂志,2015,17(9):12-15.
[4]陈为,王善林,周龙书,等.紫杉醇联合卡铂周疗和三周疗法治疗上皮性卵巢癌的疗效比较[J].中国现代医生,2013,51(17):37-39.
[5]王丹丹,史长松.重组人干扰素α-1b雾化治疗小儿呼吸道病毒感染性疾病临床对照研究[J].中国基层医药,2014,30(31):5387-5389.
[6]夏六兵,龙洲,张腾,等.干扰素α-1b联合环氧化酶-2抑制剂对肾癌细胞及其裸鼠移植瘤的抑制作用[J].局解手术学杂志,2016,25(3):157-162.
[7]杨学宁,吴一龙.实体瘤治疗疗效评价标准—RECIST[J].循证医学,2004,4(2):85-90.
[8]万崇华,方积干,汤学良,等.SF-36量表用于肝癌患者生活质量测定的效果评价[J].肿瘤,2005,25(5):492-494.
[9]图妮沙古丽·阿卜拉江.卵巢癌早期诊断相关因子研究进展[J].新乡医学院学报,2013,30(10):835-837.
[10]付清茹,齐红岩,荣安娜.晚期卵巢上皮癌新辅助化疗的研究进展[J].医学综述,2017,23(5):891-895.
[11]靳亚阁,唐其柱.干扰素基因刺激蛋白的研究进展[J].医学综述,2017,23(20):3973-3978.
[12]杨文艺,胡镜宙.干扰素和自噬在肿瘤免疫微环境中的研究进展[J].医学研究生学报,2017,30(3):319-323.
[13]方煜蓉.重组人干扰素α-1b注射液联合聚甲酚磺醛溶液治疗宫颈HPV感染临床观察[J].中国现代医药杂志,2012,14(12):76-77.
[14]郭若一,韩嫣,胡洁,等.胞质DNA受体及其对干扰素调控作用研究进展[J].国际免疫学杂志,2014,37(6):479-484.
[15]Kiyota T,Takahashi Y,Watcharanurak K,et al.Enhancement of anticancer effect of interferon-γgene transfer against interferon-γ-resistant tumor by depletion of tumor-associated macrophages[J].Mol Pharm,2014,11(5):1542-1549.
[16]张雪,顾觉奋.埃博霉素类药物在治疗非小细胞肺癌方面研究进展:抗紫杉醇耐药有效的新颖微管蛋白抑制剂[J].国外医药:抗生素分册,2013,34(1):47-48.